New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?
出版年份 2021 全文链接
标题
New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?
作者
关键词
Cardiovascular risk, Dyslipidaemia, Guidelines, Low-density lipoprotein cholesterol, Lipid-lowering therapy, Secondary prevention
出版物
ATHEROSCLEROSIS
Volume 319, Issue -, Pages 51-61
出版商
Elsevier BV
发表日期
2021-01-18
DOI
10.1016/j.atherosclerosis.2020.12.013
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
- (2020) Sotirios Tsimikas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Bempedoic Acid on Serum Uric Acid and Related Outcomes: A Systematic Review and Meta-analysis of the available Phase 2 and Phase 3 Clinical Studies
- (2020) Arrigo F. G. Cicero et al. DRUG SAFETY
- Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial
- (2019) Michelle L. O'Donoghue et al. CIRCULATION
- Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
- (2019) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY OUTCOMES Trial
- (2019) J. Wouter Jukema et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Lipid-Lowering Agents
- (2019) Robert A. Hegele et al. CIRCULATION RESEARCH
- Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance
- (2019) Ulrich Laufs et al. Journal of the American Heart Association
- Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials
- (2019) Kausik K. Ray et al. ATHEROSCLEROSIS
- Rounding the corner on residual risk: Implications of REDUCE-IT for omega-3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease
- (2019) Seth J. Baum et al. CLINICAL CARDIOLOGY
- The myth of ‘stable’ coronary artery disease
- (2019) Keith A. A. Fox et al. Nature Reviews Cardiology
- Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy
- (2019) Christie M Ballantyne et al. European Journal of Preventive Cardiology
- Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials
- (2019) Nicholas A. Marston et al. CIRCULATION
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery
- (2019) Shaun G. Goodman et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS)
- (2019) Konstantinos C. Koskinas et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options
- (2019) Kausik K Ray et al. LANCET
- Atherosclerosis
- (2019) Peter Libby et al. Nature Reviews Disease Primers
- Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels
- (2019) Kausik K. Ray et al. JAMA Cardiology
- Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease
- (2019) Anne C. Goldberg et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Bempedoic Acid for Lowering LDL Cholesterol
- (2019) Michael C. Honigberg et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes
- (2019) Daniel F. Gudbjartsson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study
- (2018) Christie M. Ballantyne et al. ATHEROSCLEROSIS
- Lipoprotein (a) levels and outcomes in stable outpatients with symptomatic artery disease
- (2018) Juan F. Sanchez Muñoz-Torrero et al. ATHEROSCLEROSIS
- Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: An Analysis from FOURIER
- (2018) Marc S. Sabatine et al. CIRCULATION
- Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1
- (2018) Kausik K. Ray et al. CIRCULATION
- Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
- (2018) Stuart J Connolly et al. LANCET
- Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
- (2018) Sonia S Anand et al. LANCET
- Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks
- (2018) Theingi Aung et al. JAMA Cardiology
- Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial
- (2018) Konstantinos C. Koskinas et al. CLINICAL CARDIOLOGY
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial
- (2018) Lawrence A. Leiter et al. DIABETES CARE
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial
- (2018) Marc P Bonaca et al. Lancet Diabetes & Endocrinology
- 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)
- (2017) Victor Aboyans et al. EUROPEAN HEART JOURNAL
- 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
- (2017) Donald M. Lloyd-Jones et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
- (2017) John W. Eikelboom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
- (2017) Marc P. Bonaca et al. CIRCULATION
- Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome
- (2016) Eliano P. Navarese et al. ANNALS OF INTERNAL MEDICINE
- Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease
- (2016) Marc P. Bonaca et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Máxima reducción de colesterol unido a lipoproteínas de baja densidad alcanzable con combinaciones farmacológicas. Cuando 50 más 20 suma 60
- (2016) Lluis Masana et al. REVISTA ESPANOLA DE CARDIOLOGIA
- Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
- (2016) Lancet Diabetes & Endocrinology
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease
- (2013) Peter P. Toth et al. Journal of Clinical Lipidology
- Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease
- (2012) Deepti Gurdasani et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
- (2011) Colin Baigent et al. LANCET
- A Prospective Natural-History Study of Coronary Atherosclerosis
- (2011) Gregg W. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
- (2009) Bengt C. Fellström et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started